Next Generation Biomarkers. A Journey of Multiomic Translational Science from Discovery to Companion Diagnostics, Upcoming Webinar Hosted by Xtalks Share Article In this free webinar, the featured speaker will discuss the application of Medicover’s technology platforms and analytics to identify suitable biomarker targets. Attendees will learn about experimental design considerations for biomarker hypothesis generation, testing and validation as well as data analytics and applications for machine learning and artificial intelligence. Access to patients and biospecimens, adherence to quality systems, understanding of the regulatory landscape, clinical feasibility considerations, and market access capabilities are critical to success. TORONTO (PRWEB) June 09, 2021 With the emergence of new biological insights through mulit-omics technologies and the development of new therapeutic concepts such as immuno-oncology, the complexity and utility of biomarkers has dramatically increased over the last decade. At the same time, our data mining and AI capabilities have opened massive opportunities from biomarker discovery to companion diagnostic commercialization. On the other hand, the ever-increasing amount of data and complexity presents new challenges in biomarker development: from Discovery, Validation and Regulatory Approval. To improve the probability of success and speed to market, an integrated approach is required. Access to patients and biospecimens, adherence to quality systems, understanding of the regulatory landscape, clinical feasibility considerations, and market access capabilities are critical to success.